Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
Author:
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference15 articles.
1. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
2. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis
3. New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future
4. Delamanid: First Global Approval
5. Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Molecular diagnostics and potential therapeutic options for mycobacterium tuberculosis: Where we stand;Medicine in Omics;2023-06
2. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis;International Journal of Infectious Diseases;2022-11
3. Novel treatments in multidrug-resistant tuberculosis;Current Opinion in Pharmacology;2021-08
4. Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid;Microorganisms;2021-05-17
5. Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance;Future Journal of Pharmaceutical Sciences;2021-03-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3